Compounds > plicamycin
Page last updated: 2024-08-23

plicamycin and Pancreatic Neoplasms

plicamycin has been researched along with Pancreatic Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chang, DZ; Gao, Y; Huang, S; Jia, Z; Le, X; Li, Q; Wang, L; Wei, D; Xie, K; Yao, JC; Zhang, J1
Chou, TC1
Jia, Z; Le, X; Li, Q; Wang, L; Wei, D; Xie, K; Yao, J; Yuan, P; Zhang, J1
Jia, Z; Le, X; Li, Q; Wang, H; Wang, L; Wei, D; Xie, K; Yao, J; Yuan, P; Zhang, J1

Other Studies

4 other study(ies) available for plicamycin and Pancreatic Neoplasms

ArticleYear
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.
    Cancer research, 2010, Feb-01, Volume: 70, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Body Weight; Cell Line, Tumor; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; ortho-Aminobenzoates; Pancreatic Neoplasms; Plicamycin; Promoter Regions, Genetic; Protein Binding; Sp1 Transcription Factor; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
Combined treatment of pancreatic cancer with mithramycin a and tolfenamic Acid promotes sp1 degradation and synergistic antitumor activity--letter.
    Cancer research, 2011, Apr-01, Volume: 71, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Humans; ortho-Aminobenzoates; Pancreatic Neoplasms; Plicamycin; Sp1 Transcription Factor

2011
Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
    Cancer research, 2007, May-15, Volume: 67, Issue:10

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Plicamycin; Promoter Regions, Genetic; Sp1 Transcription Factor; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2007
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
    Cancer, 2007, Dec-15, Volume: 110, Issue:12

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Pancreatic Neoplasms; Plicamycin; RNA, Small Interfering; Sp1 Transcription Factor; Xenograft Model Antitumor Assays

2007